Aadi Bioscience (NASDAQ:AADI – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.02, MarketWatch Earnings reports. During the same period last year, the company posted ($0.90) EPS.
NASDAQ:AADI traded up $1.37 during trading hours on Friday, hitting $14.02. 134,672 shares of the stock traded hands, compared to its average volume of 102,946. The firm has a 50 day moving average price of $16.63 and a 200 day moving average price of $20.15. Aadi Bioscience has a fifty-two week low of $11.00 and a fifty-two week high of $49.80.
A number of equities research analysts have recently commented on the company. Zacks Investment Research downgraded Aadi Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, January 25th. HC Wainwright cut their price objective on Aadi Bioscience from $49.00 to $48.00 and set a “buy” rating for the company in a research report on Monday, April 11th. Finally, Piper Sandler cut their price objective on Aadi Bioscience from $50.00 to $30.00 in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Aadi Bioscience has a consensus rating of “Buy” and a consensus price target of $40.20.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its stake in shares of Aadi Bioscience by 8.6% in the first quarter. Renaissance Technologies LLC now owns 139,522 shares of the company’s stock worth $2,368,000 after acquiring an additional 11,000 shares during the last quarter. BlackRock Inc. increased its stake in shares of Aadi Bioscience by 1,804.9% in the fourth quarter. BlackRock Inc. now owns 309,554 shares of the company’s stock worth $7,475,000 after acquiring an additional 293,304 shares during the last quarter. Susquehanna International Group LLP acquired a new position in shares of Aadi Bioscience in the fourth quarter worth $530,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Aadi Bioscience in the fourth quarter worth $381,000. Finally, Marshall Wace LLP acquired a new position in shares of Aadi Bioscience in the fourth quarter worth $704,000. 62.56% of the stock is currently owned by institutional investors and hedge funds.
About Aadi Bioscience (Get Rating)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.
- Get a free copy of the StockNews.com research report on Aadi Bioscience (AADI)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.